[1] Ubel P.A, Abernethy A.P, Zafar S.Y. Full Disclosure - Out-of-Pocket Costs as Side Effects[J]. New England Journal of Medicine.2013;369(16):1484-1486.
[2] Budnitz DS, Lovegrove M.C, Shehab N,et al. Emergency Hospitalizations for Adverse Drug Events in Older Americans[J].New England Journal of Medicine. 2011;365(21):2002-2012.
[3] Ren M, Qin H, Ren R, et al. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases[J]. Cancer Research.2011;71(23):7312-7322.
[4] Eide C.A, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile[J].Cancer Research.2011;71(9):3189-3195.
[5] Duque A.J, Lin C.H, Han K, et al. CBP modulates sensitivity to Dasatinib in Pre-BCR acute lymphoblastic leukemia[J]. Cancer Research.2018;78(22):6497-6508.
[6] Oliver O, Giuseppe S, Apperley JF, et al. Long-term efficacy and safety of Dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of Imatinib[J].Blood Cancer .2018;8(9):88.
[7] Huang X.J, Jiang Q, Hu J.D, et al. Four-year follow-up of patients with Imatinib-resistant or intolerant chronic myeloid leukemia receiving Dasatinib: efficacy and safety[J]. Frontiers of Medicine.2019;13(3):344-353.
[8] Steegmann J.L, Cervantes F, Le Coutre P, et al. Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.[J]Leukemia & Lymphoma.2012; 53(12):2351-2361.
[9] Justice J.N, Nambiar A.M, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study[J]. EBIO Medicine.2019;40:554-563.
[10] Cortes J.E, Saglio G, Kantarjian H.M, et al. Final 5-Year study results of DASISION: The Dasatinib versus Imatinib study in treatment-Naïve chronic myeloid leukemia patients trial[J].Journal of Clinical Oncology.2016;34(20):2333-2340.
[11] Hughes T.P, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving Dasatinib therapy for Philadelphia chromosome-positive leukemia[J]. Haematologica.2019;104(1):93-101.
[12]Andrew M.B,Daniel B.C,Rebecca S.H.t,et al. Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung[J]. Journal of Thoracic Oncology.2013;8(11):1434-1437.
[13] Daccord C, Letovanec I, Yerly P, et al. First histopathological evidence of irreversible pulmonary vascular disease in Dasatinib-induced pulmonary arterial hypertension[J]. European Respiratory Journal.2018;51(3).
[14]Weatherald J, Chaumais M.C, Savale L,et al. Long-term outcomes of Dasatinib-induced pulmonary arterial hypertension: a population-based study[J]. The European Respiratory Journal.2017;50(1).
[15] Calizo R.C, Bhattacharya S, van Hasselt JGC, et al. Disruption of podocyte cytoskeletal biomechanics by Dasatinib leads to nephrotoxicity[J].Nature Communications.2019;10(1):2061.
[16]Quintás-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving Dasatinib therapy[J]. Cancer.2009;115(11):2482-2490.
[17]Brave M,Goodman V,Kaminskas E, et al.Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate[J]. Clinical Cancer Research.2008;14(2):352-359.
[18]Outmanoeuvre A, ColomFernández B, Jiménez A.M, et al. Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner[J]. Clinical Cancer Research. 2017;23(21):6697-6707.
[19] Cao G.S, Jiang N, Hu Y, et al. Ruscogenin attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway[J].International Journal of Molecular Sciences. 2016; 17(9):1418-1435.
[20] Shi Y , Zhang L , Pu H , et al. Rapid endothelial cytoskeletal reorganization enables early blood–brain barrier disruption and long-term ischaemic reperfusion brain injury[J]. Nature Communications, 2016, 7:10523-10541.
[21]Liu Liu,Ping Zhang,Zhaosi Zhang,et al. LXA4 ameliorates cerebrovascular endothelial dysfunction by reducing acute inflammation after subarachnoid hemorrhage in rats[J]. Neuroscience,2019,408:105-114.
[22] Vaibhav K, Braun M, Khan M.B, et al .Remote ischemic post-conditioning promotes hematoma resolution via AMPK-dependent immune regulation[J]. The Journal of Experimental Medicine.2018;215(10):2636-2654.
[23]Phan Carole,Jutant Etienne-Marie,Tu Ly, et al. Dasatinib increases endothelial permeability leading to pleural effusion[J].The European respiratory journal,2018,51(1):218-222.
[24] Dasgupta S.K, Le A, Vijayan KV, et al. Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway[J]. Cancer Medicine.2017;6(4):809-818.
[25]Yuanyuan Z , Yuwei H , Yazheng Z , et al. DT-13 Ameliorates TNF-α-Induced Vascular Endothelial Hyperpermeability via Non-Muscle Myosin IIA and the Src/PI3K/Akt Signaling Pathway[J]. Frontiers in Immunology, 2017, 8:925-936.
[26]Li Y , Liu Y , Yan X , et al. Pharmacological Effects and Mechanisms of Chinese Medicines Modulating NLRP3 Inflammasomes in Ischemic Cardio/Cerebral Vascular Disease[J]. The American Journal of Chinese Medicine, 2018, 46(08):1727-1741.
[27]Guan T , Liu Q , Qian Y , et al. Ruscogenin reduces cerebral ischemic injury via NF-κB-mediated inflammatory pathway in the mouse model of experimental stroke[J]. European Journal of Pharmacology, 2013, 714(1-3):303-311.
[28]Ghulam Jilany Khan,Mohsin Rizwan,Muhammad Abbas, et al.. Pharmacological effects and potential therapeutic targets of DT-13[J]. Biomedicine & Pharmacotherapy,2018,97:255-263.
[29] Liu H, Yu X, Yu S, et al. Molecular mechanisms in lipopolysaccharide-induced pulmonary endothelial barrier dysfunction[J]. International Immunopharmacology.2015;29(2):937-946.
[30]Nishiwaki S, Maeda M, Yamada M, et al. Clinical efficacy of fecal occult blood test and colonoscopy for Dasatinib-induced hemorrhagic colitis in CML patients[J]. Blood.2017;129(1):126-128.
[31]Jain P, Kantarjian H, Alattar ML.,et al .Long-term molecular and cytogenetic response and survival outcomes with Imatinib 400 mg, Imatinib 800 mg, Dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials[J].The Lancet Haematolog.2015;2(3):e118-28.
[32]Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria[J]. Science. 2015;350(6262):830-834.
[33]Spadoni I,Fornasa G,and Rescigno M.Organ-specific protection mediated by cooperation between vascular and epithelial barriers[J].Nature Reviews Immunology.2017;17(12):761-773.
[34]Danese S, Sans M, de la Motte C,et al.Angiogenesis as a Novel Component of Inflammatory Bowel Disease Pathogenesis[J]. Gastroenterology.2006;130(7):2060-2073.
[35]Danese S,Panés J.Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases[J]. Gastroenterology.2014;147(5):981-989.
[36]He Y,Yuan XM,Zuo H,et al. Berberine Exerts a Protective Effect on Gut-Vascular Barrier via the Modulation of the Wnt/Beta-Catenin Signaling Pathway During Sepsis[J].Cellular Physiology and Biochemistry. 2018; 49(4):1342 - 1351.
[37]Kim Y, West GA, Ray G, et al. Layilin is critical for mediating hyaluronan 35 kDa-induced intestinal epithelial tight junction protein ZO-1 in vitro and in vivo[J]. Matrix Biology.2017;66:93-109.
[38] Guo J, Cai H, Ma J, et al. Long non-coding RNA NEAT1 regulates permeability of the blood-tumor barrier via miR-181d-5p-mediated expression changes in ZO-1, occludin, and claudin-5[J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2017;1863(9):2240-2254.
[39] Tornavaca O, Chia M, Dufton N, et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation[J]. The Journal of Cell Biology.2015; 208(6):821-838.
[40]Komarova Y.A, Kruse K, Mehta D, et al. Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability[J]. Circulation Research.2017;120(1):179-206.
[41]Bazzoni G, and Dejana E. Endothelial Cell-to-Cell Junctions: Molecular Organization and Role in Vascular Homeostasis[J].Physiological Reviews.2004;84(3):869-901.
[42] Langer V, Vivi E, Regensburger D,et al. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin–directed vascular barrier disruption[J].Journal of Clinical Investigation.2019 ;129(11):4691-4707.
[43]Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability[J]. Journal of Cell Science.2008;121(13):2115-2122.
[44] Gover P.A, Granot G, Pasmanik C.M, et al. Bosutinib, Dasatinib, Imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells[J]. Leuk Lymphoma.2019;60(1):189-199.
[45] Polacheck WJ,Kutys M.L, Yang J,et al. A non-canonical Notch complex regulates adherens junctions and vascular barrier function[J]. Nature.2017;552(7684):258-262.
[46] Han Ji,Zhang G,Welch EJ, et al. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function[J].Blood.2013;122(25):4140-4149.
[47] Gorovoy M, Han J, Pan H, et al. LIM Kinase 1 Promotes Endothelial Barrier Disruption and Neutrophil Infiltration in Mouse Lungs[J]. Circulation Research.2009;105(6):549-556.
[48]Teng JF, Qin DL, Mei QB,et al. Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer[J]. Pharmacological Research.2019;147:104396.
[49]Huang YL.,Kou JP,Ma L.,et al. Possible mechanism of the anti-inflammatory activity of ruscogenin: role of intercellular adhesion molecule-1 and nuclear factor-kappaB[J]. Journal of Pharmacological Sciences. 2008; 108(2): 198-205.
[50]Parim B,Sathibabu Uddandrao VV,Saravanan G. Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy[J].Heart Failure Reviews.2019;24(2):279-299.
[51]Magierowska K, Korbut E, Hubalewska-Mazgaj M, et al. Oxidative gastric mucosal damage induced by ischemia/reperfusion and the mechanisms of its prevention by carbon monoxide-releasing tricarbonyldichlororuthenium (II) dimer[J].Free Radical Biology and Medicine.2019;145:198-208.
[52]Li X.X, Ling S.K, Hu M.Y,et al. Protective effects of acarbose against vascular endothelial dysfunction through inhibiting Nox4/NLRP3 inflammasome pathway in diabetic rats[J].Free Radical Biology and Medicine. 2019;145:175-186.
[53]Wen J, Xu B, Sun Y, et al. Paeoniflorin protects against intestinal ischemia/reperfusion by activating LKB1/AMPK and promoting autophagy[J].Pharmacological Research.2019;146:104308-104320.